Share on StockTwits

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are presently covering the company, AnalystRatings.Net reports. One analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $41.70.

ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 34.79 on Friday. ISIS Pharmaceuticals has a one year low of $22.25 and a one year high of $62.66. The stock’s 50-day moving average is $32.17 and its 200-day moving average is $37.56. The company’s market cap is $4.096 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter last year, the company posted ($0.09) earnings per share. ISIS Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. On average, analysts predict that ISIS Pharmaceuticals will post $-0.73 earnings per share for the current fiscal year.

In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke sold 16,000 shares of the company’s stock on the open market in a transaction dated Friday, August 1st. The stock was sold at an average price of $30.53, for a total value of $488,480.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

A number of research firms have recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $35.00 price target on the stock. Analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.